Roflumilast N-oxide free base

Roflumilast N-oxide is a phosphodiesterase 4 inhibitor.

For research use only. Not for human or veterinary use.

Target Drug Metabolite Phosphodiesterase (PDE)

Research area Inflammation/Immunology

Purity >99% Stock Inquire

Data Sheet SDS COA

Roflumilast N-oxide structure

CAS No.: 292135-78-5

Download structure (.mol)

Pack sizes & pricing

Size	Price	SKU	Stock
1 g	USD 720.00	BP-02059-1g	In stock	Get quote
5 g	USD 2,520.00	BP-02059-5g	In stock	Get quote
10 g	Inquire	BP-02059-10g	Inquire	Inquire

Need another size or custom synthesis? Request a quote.

Description

Roflumilast N-oxide is a phosphodiesterase 4 inhibitor. Roflumilast N-Oxide in Combination with Formoterol Enhances the Antiinflammatory Effect of Dexamethasone in Airway Smooth Muscle Cells. Roflumilast n-oxide associated with PGE2 prevents the neutrophil elastase-induced production of chemokines by epithelial cells.

Biological activity

In Vitro Roflumilast N-oxide at 2 nM partly mitigates the cigarette smoke extract (CSE)-induced epithelial to mesenchymal transition (EMT) in WD-HBEC in vitro. Roflumilast N-oxide (2 nM) reverses the compromised expression of E-cadherin transcripts following CSE by 45%. The expression of collagen type I is abrogated by Roflumilast N-oxide (2 nM). The epithelial cell phenotype appears protected when cells are co-incubated with Roflumilast N-oxide (2 nM). Pre-incubation with Roflumilast N-oxide (2 nM) also partly attenuates the nuclear translocation of β-catenin. In Vivo Single treatment of db/db mice with 10 mg/kg Roflumilast N-oxide enhances plasma glucagon-like peptide-1 (GLP-1) 4-fold. Chronic treatment of db/db mice with Roflumilast N-oxide at 3 mg/kg shows prevention of disease progression. Roflumilast-N-oxide abolishes the increase in blood glucose, reduces the increment in HbA1c by 50% and doubles fasted serum insulin compare with vehicle, concomitants with preservation of pancreatic islet morphology. Furthermore, Roflumilast-N-oxide amplifies forskolin-induced insulin release in primary islets. Roflumilast-N-oxide also shows stronger glucose-lowering effects than its parent compound.

Identifiers

SMILES: O=C(C1=CC=C(C(OCC2CC2)=C1)OC(F)F)NC3=C(C=N(C=C3Cl)=O)Cl
InChIKey: PCGSQNPMMSALEJ-UHFFFAOYSA-N

Specifications

MW (average): 419.2070
Formula: C₁₇H₁₄Cl₂F₂N₂O₄
CAS No.: 292135-78-5
Physical state: Solid
Color: White to off-white
Shipping: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -20°C, 1 month

Solubility

Soluble in DMSO : 250 mg/mL

Documents

References

[1]. Victoni T, Gicquel T, Bodin A, et al. Roflumilast n-oxide associated with PGE2 prevents the neutrophil elastase-induced production of chemokines by epithelial cells. Int Immunopharmacol. 2016;30:1-8. doi:10.1016/j.intimp.2015.11.019

[2]. Milara J, Peiró T, Serrano A, et al. Simvastatin Increases the Ability of Roflumilast N-oxide to Inhibit Cigarette Smoke-Induced Epithelial to Mesenchymal Transition in Well-differentiated Human Bronchial Epithelial Cells in vitro. COPD. 2015;12(3):320-331. doi:10.3109/15412555.2014.948995

[3]. Vollert S, Kaessner N, Heuser A, et al. The glucose-lowering effects of the PDE4 inhibitors roflumilast and roflumilast-N-oxide in db/db mice. Diabetologia. 2012;55(10):2779-2788. doi:10.1007/s00125-012-2632-z

Same target

Search Drug Metabolite

Same research area

Search Inflammation/Immunology